{
    "clinical_study": {
        "@rank": "156540", 
        "arm_group": [
            {
                "arm_group_label": "roflumilast", 
                "arm_group_type": "Experimental", 
                "description": "500\u00b5g roflumilast qd for 4 weeks"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 pill qd for 4 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the proposed study is to test the hypothesis that in patients with\n      stable COPD who use ICS regularly, a single dose of and long-term treatment of 4 weeks with\n      roflumilast increase Qaw (not affected by ICS) and potentiate albuterol-induced vasodilation\n      in the airway beyond the preexisting effect of ICS. These vascular effects of roflumilast\n      can be considered to be anti-inflammatory. A secondary objective is to determine if\n      roflumilast potentiates albuterol-induced bronchodilation, potentially a useful effect in\n      acutely exacerbated COPD."
        }, 
        "brief_title": "Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Pulmonary Disease, Chronic Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "Participants will be on this study for about three months There will be 6 study days\n      (visits). The patients will be asked to come to the research laboratory in the morning of\n      the study day. They will be instructed to abstain from ingesting alcoholic beverages or\n      using PDE5 inhibitors the night before the study, and from consuming coffee or caffeinated\n      drinks in the morning of the study day because of their potential acute cardiovascular\n      actions. The patients will also be asked not to have a fatty breakfast on the study day to\n      avoid potential effects of fat on the absorption of roflumilast.\n\n      The visits will be separated by at least 48 hours.\n\n      The treatments will be administered in a double-blind randomized design, using active\n      roflumilast and identically appearing roflumilast placebo provided by Forest."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Twenty-four patients with physician-diagnosed COPD (female and male, current smokers\n             or ex-smokers) over the age of 45 years will be recruited for this study.\n\n          -  The patients will have to have a smoking history of at least 10 pack-years, and they\n             must have been using an ICS regularly for at least 4 weeks at the time of screening.\n\n          -  Confirmation of the diagnosis of COPD will require the presence of persistent\n             exertional dyspnea and a post-bronchodilator FEV1 of less than 80% of predicted and\n             FEV1/FVC ratio less than 0.7 (GOLD stage \u22652). At entry into the study, the patients\n             will have to be clinically stable; they will be allowed to remain on their regular\n             COPD treatment regimen and use a LABA and/or LAMA until 24 hours before, and a SABA\n             and/or short-acting muscarinic antagonist (SAMA) until 6 hours before coming to the\n             laboratory. If using roflumilast, the subjects will have to discontinue it 4 weeks\n             before entering into the study.-\n\n        Exclusion Criteria:\n\n          -  Women of childbearing potential who do not use accepted birth control measures\n\n          -  Pregnant and breast-feeding women.\n\n          -  Use of cardiovascular medications that cannot be held on the study days\n\n          -  Use of oral airway medications or anti-inflammatory agents\n\n          -  Use of supplemental oxygen that cannot be discontinued during the laboratory visit\n\n          -  Subjects with known SABA or roflumilast intolerance\n\n          -  An acute COPD exacerbation within four weeks prior to the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097992", 
            "org_study_id": "DAL-IT-06"
        }, 
        "intervention": [
            {
                "arm_group_label": "roflumilast", 
                "intervention_name": "roflumilast", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "airway blood flow"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "contact": {
                "email": "emendes@med.miami.edu", 
                "last_name": "Eliana Mendes", 
                "phone": "305-243-2568"
            }, 
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33136"
                }, 
                "name": "University of Miami Divison of Pulmonary and Critical Care Medicine"
            }, 
            "investigator": {
                "last_name": "Adam Wanner, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD", 
        "other_outcome": [
            {
                "description": "Participants will be  given either 500\u00b5g roflumilast or placebo, blinded to patient and investigator. One hour later, FEV1 will be measured before and 15 min after the inhalation of 180\u00b5g albuterol using a spacer. These measurements are to determine if roflumilast potentiates albuterol-induced bronchodilation, potentially a useful effect in acutely exacerbated COPD.", 
                "measure": "Change from baseline on albuterol-induced bronchodilation (delta FEV1) after a single dose of roflumilast.", 
                "safety_issue": "No", 
                "time_frame": "baseline, 15, 30, 60,120 and 240 min after the oral administration of either 500\u00b5g roflumilast or placebo"
            }, 
            {
                "description": "Participants will be  given either 500\u00b5g roflumilast or placebo, blinded to patient and investigator. One hour later, FEV1 will be measured before and 15 min after the inhalation of 180\u00b5g albuterol using a spacer. These measurements are to determine if roflumilast potentiates albuterol-induced bronchodilation, potentially a useful effect in acutely exacerbated COPD.", 
                "measure": "Change from baseline on albuterol-inducted bronchodilation (delta FEV1) after a 4-week treatment of roflumilast.", 
                "safety_issue": "No", 
                "time_frame": "baseline and  15 minutes after albuterol inhalation."
            }
        ], 
        "overall_contact": {
            "email": "emendes@med.miami.edu", 
            "last_name": "Eliana Mendes", 
            "phone": "(305)243-2568"
        }, 
        "overall_contact_backup": {
            "email": "awanner@med.miami.edu", 
            "last_name": "adam wanner", 
            "phone": "(305)243-2568"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary objective of the proposed study is to test the hypothesis that in patients with stable COPD who use ICS regularly, a single dose of roflumilast increase Qaw.", 
                "measure": "Change from baseline on airway blood flow (Qaw) after single dose of roflumilast .", 
                "safety_issue": "No", 
                "time_frame": "baseline, and at 15, 30, 60,120 and 240 min after the oral administration of either 500\u00b5g roflumilast or placebo (lactose an inactive substance)."
            }, 
            {
                "description": "Participants will be  given either 500\u00b5g roflumilast or placebo, blinded to patient and investigator. One hour later, Qaw will be measured before and 15 min after the inhalation of 180\u00b5g albuterol using a spacer.", 
                "measure": "Change from baseline on albuterol-induced vasodilation in the airway (delta Qaw) after a single dose of roflumilast.", 
                "safety_issue": "No", 
                "time_frame": "baseline and 1 hour later administration of roflumilast or placebo"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097992"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Miami", 
            "investigator_full_name": "Adam Wanner", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Participants will be given a 4-week treatment of roflumilast or placebo. At the end of the treatment, Qaw will be measured before and 15 min after the inhalation of 180\u00b5g albuterol.", 
            "measure": "Change from baseline on albuterol-inducted vasodilation on the airway after a 4-week treatment of roflumilast.", 
            "safety_issue": "No", 
            "time_frame": "Baseline and at 15 min after the inhalation of 180 \u00b5g albuterol"
        }, 
        "source": "University of Miami", 
        "sponsors": {
            "collaborator": {
                "agency": "Forest Laboratories", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Miami", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}